Skip to main content

Table 4 Robustness checks on changes in initiation of AET after state health reform in low-income areas vs. high-income area

From: Changes in initiation of adjuvant endocrine therapy for breast cancer after state health reform

  (1) (2) (3)
Breast cancer patients who are both ER and PR positive Excluding patients with in situ disease at diagnosis1 Adjusting for county-level controls2
Breast cancer patients aged 20–64 years 0.038*** 0.049*** 0.051***
[0.106, 0.065] [0.021, 0.076] [0.025, 0.077]
N 17,725 15,543 20,551
Breast cancer patients aged 20–49 years 0.056** 0.087*** 0.068***
[0.012, 0.100] [0.040, 0.133] [0.026, 0.110]
N 7110 5801 7960
Breast cancer patients aged 50–64 years 0.025 0.026 0.040**
[−0.009, 0.060] [−0.009, 0.061] [0.007, 0.072]
N 10,615 9652 12,591
  1. These robustness checks were conducted in the main multivariable difference-in-differences regressions in Table 2, which controls for age at diagnosis, marital status, race/ethnicity, stage at diagnosis, and type of surgery
  2. AET Adjuvant Endocrine Therapy, ER Estrogen Receptor, PR Progesterone receptor
  3. ***p-value< 0.01 **p-value< 0.05
  4. aDerived American Joint Committee on Cancer (AJCC) stage = 0
  5. bMedian household income, percent unemployed, percent with less than a high school education, percent non-Hispanic white, percent urban; and primary care physicians, specialist physicians, safety net provider, and hospital beds all specified as rate per 1000 population